Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-007032.pdf
0001415889-24-007032.rtf
0001415889-24-007032.xls
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

 View HTML
0001950047-24-001814.pdf
0001950047-24-001814.rtf
0001950047-24-001814.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-006053.pdf
0001415889-24-006053.rtf
0001415889-24-006053.xls
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

 View HTML
0001950047-24-001497.pdf
0001950047-24-001497.rtf
0001950047-24-001497.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-24-026343.pdf
0001104659-24-026343.rtf
0001104659-24-026343.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
S-8

Securities offered to employees pursuant to employee benefit plans

 View HTML
0001104659-24-024937.pdf
0001104659-24-024937.rtf
0001104659-24-024937.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-24-001197.pdf
0001558370-24-001197.rtf
0001558370-24-001197.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-K

Annual report which provides a comprehensive overview of the company for the past year

 View HTML
0001558370-24-001254.pdf
0001558370-24-001254.rtf
0001558370-24-001254.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000080255-24-000713.pdf
0000080255-24-000713.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-003825.pdf
0001415889-24-003825.rtf
0001415889-24-003825.xls